Showing results (201-210 of 217) with videos related to

Sort By:
Pageof 22
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 14, 2025
Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus TremelimumabTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter studyAtsushi Naganuma, Satoru Kakizaki, Takeshi Hatanaka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 7, 2025
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and BevacizumabTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 25, 2025
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre StudyTakeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.
Liver Cancer|October 9, 2025
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular CarcinomaKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Oncology|August 10, 2025
Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular CarcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 6, 2025
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective AnalysisTakeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.
Journal of Gastroenterology|August 20, 2025
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Medicine|February 15, 2026
Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical PracticeHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 6, 2025
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter AnalysisTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Pageof 22